Clinical trials
Completed Phase 3 trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
4,409 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 56 |
| 2001 | 67 |
| 2002 | 88 |
| 2003 | 136 |
| 2004 | 163 |
| 2005 | 207 |
| 2006 | 237 |
| 2007 | 208 |
| 2008 | 257 |
| 2009 | 213 |
| 2010 | 223 |
| 2011 | 208 |
| 2012 | 227 |
| 2013 | 229 |
| 2014 | 234 |
| 2015 | 225 |
| 2016 | 192 |
| 2017 | 223 |
| 2018 | 203 |
| 2019 | 180 |
| 2020 | 130 |
| 2021 | 132 |
| 2022 | 81 |
| 2023 | 78 |
| 2024 | 37 |
| 2025 | 6 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 4,409 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 189 |
| AstraZeneca | 179 |
| Hoffmann-La Roche | 167 |
| GlaxoSmithKline | 152 |
| Sanofi | 148 |
| Pfizer | 131 |
| Boehringer Ingelheim | 112 |
| Eli Lilly and Company | 112 |
| Bristol-Myers Squibb | 109 |
| Amgen | 93 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 210 |
| Breast Neoplasms | 134 |
| Diabetes Mellitus | 100 |
| Pulmonary Disease, Chronic Obstructive | 96 |
| Carcinoma, Non-Small-Cell Lung | 88 |
| Prostatic Neoplasms | 86 |
| Neoplasms | 83 |
| Asthma | 82 |
| Arthritis, Rheumatoid | 80 |
| Psoriasis | 79 |
Trials
Showing 1 to 25 of 4,409. Each trial links to its page on Pharma Observatory.
4,309 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.